Robert Kramer - Portage Biotech Chief Officer
| PRTG Stock | USD 4.20 0.05 1.18% |
Insider
Robert Kramer is Chief Officer of Portage Biotech
| Phone | 203 221 7378 |
| Web | https://www.portagebiotech.com |
Robert Kramer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Kramer against Portage Biotech stock is an integral part of due diligence when investing in Portage Biotech. Robert Kramer insider activity provides valuable insight into whether Portage Biotech is net buyers or sellers over its current business cycle. Note, Portage Biotech insiders must abide by specific rules, including filing SEC forms every time they buy or sell Portage Biotech'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Kramer over a month ago Acquisition by Robert Kramer of 7500 shares of Appian Corp subject to Rule 16b-3 |
Portage Biotech Management Efficiency
The company has return on total asset (ROA) of (0.1545) % which means that it has lost $0.1545 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9889) %, meaning that it created substantial loss on money invested by shareholders. Portage Biotech's management efficiency ratios could be used to measure how well Portage Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jenna Cohen | Blueprint Medicines Corp | N/A | |
| Mark Meier | Fennec Pharmaceuticals | N/A | |
| MA MS | Inozyme Pharma | N/A | |
| Alexander MS | Fennec Pharmaceuticals | N/A | |
| MBA MBA | Inozyme Pharma | 65 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Charles Winter | Janux Therapeutics | 56 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| DVM Dvm | Lineage Cell Therapeutics | 53 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Jennifer Lachey | Keros Therapeutics | 51 | |
| Brian Varnum | Armata Pharmaceuticals | 64 | |
| Alan Russell | Edgewise Therapeutics | 55 | |
| Ioana Hone | Lineage Cell Therapeutics | N/A | |
| MSc MBA | Inozyme Pharma | 53 | |
| Andy Meyer | Janux Therapeutics | 41 | |
| Dr MBA | Blueprint Medicines Corp | 55 | |
| JD MBA | Blueprint Medicines Corp | 51 | |
| Todd MBA | Armata Pharmaceuticals | 61 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Wayne MD | Janux Therapeutics | 63 | |
Management Performance
| Return On Equity | -1.99 | ||||
| Return On Asset | -0.15 |
Portage Biotech Leadership Team
Elected by the shareholders, the Portage Biotech's board of directors comprises two types of representatives: Portage Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Portage. The board's role is to monitor Portage Biotech's management team and ensure that shareholders' interests are well served. Portage Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Portage Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, CEO Board | ||
| Allan CPA, Chief Officer | ||
| Adam Melero, Controller | ||
| EunJae CPA, Chief Officer | ||
| Robert Kramer, Chief Officer | ||
| Brian Wiley, Chief Officer | ||
| Andrea Park, Chief Officer | ||
| Peter Molloy, Chief Inc | ||
| Steven Innaimo, Vice Operations | ||
| Alexander Pickett, CEO Director | ||
| Justin Fairchild, Vice Development | ||
| Joseph Ciavarella, Chief Officer |
Portage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Portage Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.99 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | 5.18 M | ||||
| Shares Outstanding | 1.65 M | ||||
| Shares Owned By Insiders | 51.37 % | ||||
| Shares Owned By Institutions | 6.19 % | ||||
| Number Of Shares Shorted | 13.03 K | ||||
| Price To Book | 4.95 X | ||||
| EBITDA | (18.2 M) | ||||
| Net Income | (75.34 M) |
Currently Active Assets on Macroaxis
When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.